Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

Background Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and its relationship with clinical outcome in the real-w...

Full description

Bibliographic Details
Main Authors: Markus Joerger, Reno Debets, Edwin A. Basak, Daan P. Hurkmans, Cor H. van der Leest, Sebastiaan D.T. Sassen, Karlijn de Joode, Lisanne Putter, Annemarie J.M. Wijkhuijs, Birgit C.P. Koch, Marco W.J. Schreurs, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002344.full

Internet

https://jitc.bmj.com/content/9/6/e002344.full

Similar Items